FDA wants companies to edit 510(k)s for public disclosure
This article was originally published in Clinica
Companies that seek to market their products via the 510(k) route in the US will soon face some additional paperwork. The FDA has proposed that manufacturers begin supplying the agency with a "redacted" copy of their 510(k) submission, ie a filing stripped of any trade secrets, confidential commercial information or patient identification.
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.